

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Grazoprevir–elbasvir for treating chronic hepatitis C [ID842]

Batch 44

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the draft scope consultation, a consultee stated that it was important to consider people with sickle cell disease (more prevalent in those with African ethnicity) and thalassaemia (southern Mediterranean and Asian ancestry).

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The Committee's recommendations are based on the clinical- and cost-effectiveness of technologies, and not based on ethnicity or family origin.

However, when making its recommendations, the Committee will consider whether any people with protected characteristics are indirectly discriminated against.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No. However, the company is encouraged to provide any data that may support any potential equality issues in its evidence submission.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Helen Knight

Date: 18/02/2016